Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.03
+22.9%
$0.06
$0.00
$0.78
$1.42M1.185,966 shs1,720 shs
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
$2.19
$2.19
$1.40
$3.88
$104.80M1.33239,104 shs800 shs
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
$1.95
$2.17
$1.50
$6.48
$13.83M1.387,484 shsN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
$1.17
+3.5%
$1.03
$0.58
$3.80
$14.93M0.553.71 million shs412,756 shs
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$0.00
$0.00
$0.00
$0.07
N/A3.0317 shs13 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
+22.88%-72.32%-2.63%+11.00%-87.97%
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
0.00%0.00%0.00%0.00%0.00%
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
0.00%0.00%0.00%0.00%0.00%
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
+3.54%-4.49%+39.39%+20.04%+28.67%
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00%0.00%0.00%-85.71%-85.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
2.0382 of 5 stars
3.62.00.00.02.40.00.6
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
0.00
N/AN/AN/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
0.00
N/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
3.25
Buy$4.00241.88% Upside
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FWP, ETTX, ADXS, HOTH, and RGRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/12/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/15/2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M0.44N/AN/A($2.06) per share-0.02
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
$7M14.97N/AN/A$0.66 per share3.32
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/A$10.09 per shareN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/A$0.86 per shareN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$80K0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
-$47.14M-$1.12N/AN/AN/AN/A-145.48%-103.75%N/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
-$1.89MN/A0.00N/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
-$1.73MN/A0.00N/AN/AN/AN/AN/A

Latest FWP, ETTX, ADXS, HOTH, and RGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$0.34-$0.27+$0.07-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/AN/AN/AN/AN/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
N/A
1.65
1.65
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/A
18.43
N/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/A
15.09
15.08
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Entasis Therapeutics Holdings Inc. stock logo
ETTX
Entasis Therapeutics
5147.85 million44.74 millionNot Optionable
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
47.09 million2.02 millionNot Optionable
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
413.21 million12.30 millionNot Optionable
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
31.51 million1.32 millionNot Optionable

Recent News About These Companies

EIGRQ Eiger BioPharmaceuticals, Inc.
The Hawryluk Biopharmaceutical Scholars
Regenerx Biopharmaceuticals Inc RGRXD
Regenerx Biopharm In (RGRXD)
RGRX RegeneRx Biopharmaceuticals, Inc.
RegeneRx To Extend Consent Solicitation Vote
Bristol-Myers to Split Off Mead Johnson

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.03 +0.01 (+22.88%)
As of 06/30/2025 11:15 AM Eastern

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Entasis Therapeutics stock logo

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Forward Pharma A/S stock logo

Forward Pharma A/S NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Hoth Therapeutics stock logo

Hoth Therapeutics NASDAQ:HOTH

$1.17 +0.04 (+3.54%)
As of 06/30/2025 04:00 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

RegeneRx Biopharmaceuticals stock logo

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 0.00 (0.00%)
As of 06/27/2025

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.